-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BOLD-100 in Gastroesophageal (GE) Junction Carcinomas
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BOLD-100 in Gastroesophageal (GE) Junction Carcinomas Drug Details: BOLD-100 (IT-139, NKP-1339) is under development for...
-
Product Insights
Gastrointestinal Tumor – Drugs In Development, 2023
Global Markets Direct’s, ‘Gastrointestinal Tumor - Drugs In Development, 2023’, provides an overview of the Gastrointestinal Tumor pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastrointestinal Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Tivozanib Hydrochloride in Bile Duct Cancer (Cholangiocarcinoma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tivozanib Hydrochloride in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: Tivozanib Hydrochloride (Fotivda) is a quinoline...
-
Product Insights
Esophageal Squamous Cell Carcinoma (ESCC) – Drugs In Development, 2023
Global Markets Direct’s, ‘Esophageal Squamous Cell Carcinoma (ESCC) - Drugs In Development, 2023’, provides an overview of the Esophageal Squamous Cell Carcinoma (ESCC) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Esophageal Squamous Cell Carcinoma (ESCC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Gastroesophageal (GE) Junction Carcinomas – Drugs In Development, 2023
Global Markets Direct’s, ‘Gastroesophageal (GE) Junction Carcinomas - Drugs In Development, 2023’, provides an overview of the Gastroesophageal (GE) Junction Carcinomas pipeline landscape. The report provides comprehensive information on the therapeutics under development for Gastroesophageal (GE) Junction Carcinomas, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BMS-986340 in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMS-986340 in Ovarian Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BMS-986340 in Ovarian Cancer Drug Details: BMS-986340 is under development for the...
-
Product Insights
Kudumane Mine
The Kudumane Mine is a manganese mine in South Africa. It is currently in operation. Empower your strategies with our Kudumane Mine report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Reasons to buy Gain vital...
-
Product Insights
Plasma Cell Neoplasm – Drugs In Development, 2023
Global Markets Direct’s, ‘Plasma Cell Neoplasm - Drugs In Development, 2023’, provides an overview of the Plasma Cell Neoplasm pipeline landscape. The report provides comprehensive information on the therapeutics under development for Plasma Cell Neoplasm, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ecopipam Hydrochloride in Tourette Syndrome
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Ecopipam Hydrochloride in Tourette Syndrome Drug Details:Ecopipam hydrochloride (PSYRX-101) is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – HZA-018 in Marginal Zone B-cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - HZA-018 in Marginal Zone B-cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.HZA-018 in Marginal Zone B-cell Lymphoma Drug Details:HZA-018 is under development...